Image result for cannabidiol gw

Epidiolex® – investigational cannabidiol formulation

Publication

  • Study: GWPCARE3
  • Authors: Devinsky, Zuberi et al
  • Journal: New England Journal of Medicine
  • Date: May 17th, 2018

Conclusions

  • Cannabidiol add-on to conventional antiepileptic therapy reduced drop seizure frequency in patients with Lennox–Gastaut syndrome
  • Both 10 mg/kg and 20 mg/kg cannabidiol effective in reducing number of seizures
  • Dose-dependent increase in adverse events relative to placebo

Advertisements

Publication 

  • New England Journal of Medicine
  • Castro & Tohda et al, May 2018

Key Points

  • Dupilumab: monoclonal antibody targets IL-4 receptor (blocks  IL-4, IL-13 response)
  • Biweekly subcutaneous injection
  • 47.7% decrease in severe asthma exacerbations w/ dupilumab vs. placebo
  • Best response (66% fewer exacerbations) if blood eosinophils > 300/mm³
  •  + 0.14 L ΔFEV1 relative to placebo (after 12 weeks)
  • Rate of adverse rxns similar in tx and ctl groups (most common: injection site reaction)

Publication 

Key Points

  • Clopidogrel + aspirin lower risk of major ischemic events (stroke, MI, vascular) relative to aspirin alone following minor stroke or high-risk TIA
  • Most risk reduction during first 30 days
  • More frequent serious bleeding events on dual therapy, although primarily gastrointestinal/systemic rather than intracerebral
  • Dual therapy benefit may outweigh risks in first 30 days after minor stroke/TIA

Publication 

Key Points

  • 47% of perioperative anaphylaxis cases were attributed to antibiotic use
  • Teicoplanin, a glycopeptide antibiotic, implicated in 38% cases of antibiotic-induced anaphylaxis (1/6 total perioperative cases)
  • 1/3 of anaphylaxis cases attributed to neuromuscular blockers
  • 40/266 anaphylaxis cases reviewed involved cardiac arrest and 10 deaths

Publication

Key Points

  • 89% of untreated infants with congenital cytomegalovirus (cCMV) infection and isolated sensorineural hearing loss (SNHL) develop significant bilateral hearing loss
  • In valganciclovir treated cohort, only 35% of cCMV w/ isolated SHNL had functional hearing loss after 4-5y
  • No deterioration of unaffected ears observed in treated cohort

Publication

Key Points

  • 78.8% decrease in childhood buprenorphine-naloxone exposures following transition to unit-dose packaging (UDP) from bulk packaging (pill bottle)
  • No decrease in single-entity buprenorphine exposures, which have not transitioned to UDP
  • Switching to UDP for single-entity buprenorphine products may lower future childhood buprenorphine exposure and hospitalization rates